💡 FDA approval and launch of generic diabetes drug in the US market.
What Happened
Lupin Limited announced the launch of Dapagliflozin and Metformin Hydrochloride Extended-Release Tablets in the United States. The company received approval from the U.S. FDA for its Abbreviated New Drug Application, confirming the product as bioequivalent to Xigduo® XR. The launch includes four dosage strengths: 5 mg/500 mg, 5 mg/1,000 mg, 10 mg/500 mg, and 10 mg/1,000 mg.
Key Details
- Company: Lupin Limited
- Event Type: Regulatory
- Filing Date: 22-Apr-2026 09:13:16
- NSE Filing: View Document
Why It Matters
This FDA approval and subsequent US market launch represents a significant regulatory milestone for Lupin. The product is a generic version of AstraZeneca's Xigduo® XR, used for diabetes treatment, entering a substantial therapeutic market. Successful generic launches in the US typically contribute to revenue growth and strengthen a pharmaceutical company's portfolio in a key regulated market. This development enhances Lupin's presence in the anti-diabetic segment and demonstrates its regulatory execution capabilities.
Disclaimer: This is publicly available information sourced from NSE. Not investment advice.
Get signals like this instantly
Free Telegram alerts within 2 minutes of NSE filing
Join SuperStock Free